Diva Laboratories (ROCO:4153) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Diva Laboratories Debt-to-Equity?

Diva Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$2.5 Mil. Diva Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$4.3 Mil. Diva Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$985.2 Mil. Diva Laboratories's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Diva Laboratories's Debt-to-Equity or its related term are showing as below:

ROCO:4153' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.36 Max: 0.68
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Diva Laboratories was 0.68. The lowest was 0.00. And the median was 0.36.

ROCO:4153's Debt-to-Equity is ranked better than
99.48% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs ROCO:4153: 0.01

Diva Laboratories Debt-to-Equity Historical Data

The historical data trend for Diva Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diva Laboratories Debt-to-Equity Chart

Diva Laboratories Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

Diva Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	0.01

Competitive Comparison of Diva Laboratories's Debt-to-Equity

For the Diagnostics & Research subindustry, Diva Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diva Laboratories's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Diva Laboratories's Debt-to-Equity falls into.

Diva Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Diva Laboratories's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.13	+	0.153)	/	1016.182
	=	0.00

Diva Laboratories's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.534	+	4.343)	/	985.182
	=	0.01

Diva Laboratories (ROCO:4153) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Diva Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Diva Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Diva Laboratories (ROCO:4153) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diva Laboratories Ltd (ROCO:4153) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

9F, No. 351 Sector 2, Chung Shan Road, Chung Ho, New Taipei City, TWN, 235

Website

http://www.diva.com.tw

Diva Laboratories Ltd is a Taiwan-based company that engages in the manufacturing and sale of a medical display. It offers endo/surgical displays; color displays for radiology and medical imaging services; touch displays; and original design manufacturing and original equipment manufacturing solutions.

Diva Laboratories (ROCO:4153) Headlines

No Headlines